Aridis Receives Agreement From FDA On A Single Confirmatory Phase 3 Study Of AR-301 And The Clinical Study Design
Portfolio Pulse from Benzinga Newsdesk
Aridis Pharmaceuticals has received agreement from the FDA for a single confirmatory Phase 3 study of AR-301 and its clinical study design. This will potentially expedite the development and approval process for the treatment.
May 31, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aridis Pharmaceuticals receives FDA agreement for a single confirmatory Phase 3 study of AR-301, potentially expediting the development and approval process.
The FDA agreement for a single confirmatory Phase 3 study of AR-301 is a positive development for Aridis Pharmaceuticals. This could potentially expedite the development and approval process for the treatment, which may positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100